Kathy Hibbs Sells 6,250 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total transaction of $54,250.00. Following the completion of the sale, the director directly owned 103,242 shares of the company’s stock, valued at approximately $896,140.56. This represents a 5.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $8.92 on Friday. The company has a market capitalization of $748.34 million, a price-to-earnings ratio of -7.76 and a beta of 0.96. SOPHiA GENETICS SA has a 1-year low of $3.10 and a 1-year high of $8.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock’s fifty day simple moving average is $6.46 and its 200-day simple moving average is $5.43.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Unusual trading volume is drawing attention to SOPH, with the stock approaching a new 12-month high. The activity suggests increased investor interest and reinforces the recent upward momentum. When Unusual Volume Isn’t Noise: 3 Small-Caps Sending Signals
• Positive Sentiment: Analyst sentiment improved after the August 5 earnings report. BTIG Research raised its price target to $9 from $8, while HC Wainwright lifted its target to $14 from $12; both firms maintained Buy ratings. The reported $23.31 million in revenue exceeded the $21.72 million consensus estimate, although the company still posted a larger-than-expected quarterly loss. The average analyst price target is approximately $10.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating little measurable short-selling pressure, but also providing limited incremental trading information.
• Negative Sentiment: Several insiders recently sold shares: CTO Abhimanyu Verma sold 5,000 shares on August 19 and another 5,000 on August 24; Director Kathy L. Hibbs sold 6,250 shares on August 25; and Philippe Menu sold 5,000 shares on August 25. The transactions reduced their individual holdings by roughly 2% to 6% and could weigh on sentiment. However, all were executed under pre-arranged Rule 10b5-1 plans, meaning they may not represent current concerns about SOPHiA GENETICS. SEC insider transaction filing
• Negative Sentiment: SOPHiA GENETICS remains unprofitable: it reported a quarterly loss of $0.26 per share versus the $0.21 consensus loss estimate, and analysts expect a full-year loss of approximately $0.77 per share. Its negative margins and continued earnings losses remain key risks despite the revenue beat and improving share-price momentum.

Wall Street Analyst Weigh In

Several research firms recently commented on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently made changes to their positions in the company. AWM Investment Company Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. Sei Investments Co. bought a new position in SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. 1492 Capital Management LLC acquired a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $973,000. Royce & Associates LP acquired a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $2,009,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS in the second quarter worth approximately $567,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.